Providing coverage for biomarker testing.

HB 1062 requires all health plans in Washington (including commercial plans, public employee coverage, and state Medicaid) to cover biomarker testing starting January 1, 2026. This applies to tests that measure biological markers in tissue or blood (like gene mutations) when used for diagnosis, treatment, or monitoring of a patient’s condition, provided the test is supported by FDA approvals, Medicare guidelines, clinical practice standards, or expert consensus. Plans must ensure coverage without causing unnecessary disruptions, such as requiring multiple biopsies. The bill mandates this coverage uniformly across all plan types under specific evidence-based criteria.